United Kingdom

People: Resverlogix Corp (RVX.TO)

RVX.TO on Toronto Stock Exchange

4:12pm BST
Change (% chg)

$0.05 (+1.80%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Johansson, Jan 

Dr. Jan O. Johansson, M.D. Ph.D. serves as Senior Vice President - Medical Affairs of Resverlogix Corp. He served as Chief Medical Officer at Nuvelo, Inc. from 2003 to 2004; Vice President, Clinical Research and Development, Lipid Sciences Inc. from 2001 to 2003; Co-Founder, Vice President, Clinical Affairs and Senior Clinical Research Fellow of Esperion Therapeutics, Inc. from 1998 to 2001. Dr. Johansson earned his MD and Ph.D. at the Karolinska Institute in Sweden and has published more than 50 peer-review medical articles.

Basic Compensation

Total Annual Compensation, CAD 183,841
Restricted Stock Award, CAD --
Long-Term Incentive Plans, CAD --
All Other, CAD 420,243
Fiscal Year Total, CAD 604,084

Options Compensation

  Quantity Market Value
Exercisable 800,000 6,042,000.00
Unexercisable -- --
Exercised -- --